HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.

Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in patients with transthyretin amyloid cardiomyopathy.

This recurrent event analysis included 611 patients from the ATTRibute-CM trial and its open-label extension, randomized to acoramidis 800 mg or placebo twice daily. The patient population had a mean ATTR-CM disease duration of 1.2 years, with 90% having wild-type disease. Investigators assessed the cumulative risk of cardiovascular mortality or recurrent cardiovascular hospitalizations over 30 months, with particular attention to the timing of treatment effect emergence and the sustained nature of clinical benefit throughout follow-up.

Findings demonstrated a significant 49% reduction in cumulative cardiovascular events at 30 months, with treatment effects evident as early as one month and divergence between groups widening progressively over time.

Interview Questions:

1. What is the current treatment landscape for ATTR-CM?
2. What were the aims of this post hoc analysis?
3. What were your key findings?
4. What do these findings tell us about the mechanism and timing of benefit with TTR stabilization?
5. What are the clinical implications of these findings for managing patients with ATTR-CM?
6. What are your key take-home messages and what are the next steps for this research?

Recorded on-site at HFSA Annual Scientific Meeting 2025.
Editors: Jordan Rance, Yazmin Sadik
Videographer: Oliver Miles
Support: This is an independent interview produced by Radcliffe Cardiology.